IOVANCE BIOTHERAPEUTICS Files 8-K
Ticker: IOVA · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-statements, exhibits
Related Tickers: IOVA
TL;DR
IOVA filed an 8-K for financial statements/exhibits. Keep an eye on updates.
AI Summary
On February 10, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial health and operational activities. No specific dollar amounts or new events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Iovance Biotherapeutics is providing updated financial information or exhibits, which could be material for investors assessing the company's current financial standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- February 10, 2025 (date) — Date of Report
- Delaware (location) — State of Incorporation
- 001-36860 (other) — Commission File Number
- 75-3254381 (other) — I.R.S. Employer Identification No.
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided excerpt states the filing concerns 'Financial Statements and Exhibits' but does not list the specific documents included.
What is the primary purpose of this 8-K filing for IOVANCE BIOTHERAPEUTICS, INC.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 10, 2025.
When was this 8-K report filed?
The report was filed on February 10, 2025.
What is IOVANCE BIOTHERAPEUTICS, INC.'s state of incorporation?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
Does this filing indicate any new material events or changes in the company's business?
The excerpt indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits', suggesting updates or disclosures rather than a specific new material event being detailed in this summary.
Filing Stats: 412 words · 2 min read · ~1 pages · Grade level 8.7 · Accepted 2025-02-10 07:22:01
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Global Mark
Filing Documents
- tm255949d1_8k.htm (8-K) — 25KB
- tm255949d1_ex99-1.htm (EX-99.1) — 14KB
- tm255949d1_ex99-1img01.jpg (GRAPHIC) — 13KB
- 0001104659-25-010729.txt ( ) — 233KB
- iova-20250210.xsd (EX-101.SCH) — 3KB
- iova-20250210_lab.xml (EX-101.LAB) — 33KB
- iova-20250210_pre.xml (EX-101.PRE) — 22KB
- tm255949d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On February 10, 2025, Iovance Biotherapeutics, Inc. (the " Company ") issued a press release announcing the appointment of Daniel Kirby as Chief Commercial Officer. The full text of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 99.1 Press release dated February 10, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 10, 2025 Iovance Biotherapeutics, Inc. By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and President, and General Counsel